DR-073 Making HMF colorectal cancer data accessible for the HMF CRC focus group through cBioPortal
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-073 Making HMF colorectal cancer data accessible for the HMF CRC focus group through cBioPortal
“Colorectal cancer (CRC) is the second most common cause of cancer death worldwide. Cancer is caused by DNA alterations. Detailed …
DR-072 Chromosomal breakpoints in colorectal cancer
“Purpose: Colorectal cancer (CRC) is the second most common cause of cancer death worldwide. Cancer is caused by DNA alterations. …
DR-055 The whole-genome landscape of advanced biliary tract cancer
Biliary tract cancer (BTC) is malignancy of bile ducts (also called cholangiocarcinoma) and gallbladder. BTC is a rare malignancy in …
DR-112 Somatic mutations and germline variants at Estrogen Receptor / DNA binding sites and their impact on gene expression programs in metastatic breast cancer
Estrogen Receptor is a hormone-responsive protein, responsible for breast tumor growth. We found that DNA-binding specificity can predict treatment response, …
DR-110 Whole-genome mutational patterns
Mutations are generated by endogenous (replication errors) and exogenous processes (UV light). Studying the mutational patterns observed across both genes …
DR-108 Genomic characterisation of Non-Melanoma Skin Cancer
Our group produces WGS data for 100 Non-Melanoma Skin Cancers (NMSC) in order to characterise mutational landscape and driver mutations …
DR-107 Impact of somatic mutations and prostate cancer risk SNPs on enhancer activity, interpatient heterogeneity and responsive gene expression in metastatic prostate cancer
We have mapped in metastatic prostate cancer how genes are being regulated. Now, we aim to combine these results with …
DR-106 Discovery of mutational signatures associated with chemotherapeutic treatment of cancer
Mutational signatures are patterns of mutations that inform us on the mutational process underlying tumorigenesis. We will investigate the mutational …
DR-104 A comprehensive analysis of mutational processes and signatures in primary and metastatic cancer tumors
Systematic analysis of cancer genomes has revealed a number of characteristic mutational signatures. Some of these have been linked to …
DR-103 BRAF and RNF43 copy number variation and mutant allele frequency in BRAF/RNF43 mutant colorectal cancer.
An aggressive subtype of colorectal cancer (CRC) harbours activating mutations in the BRAF oncogene and inactivating mutations in the RNF43 …
DR-102 Correlation analyses of genomic data, ctDNA and clinical data in patients with advanced/metastatic urothelial cell cancer (UCC) treated with anti-PD1 checkpoint inhibitors.
The treatment of bladder cancer patients with immunotherapy is a very promising and effective treatment. However, only a minority of …
DR-101 Analysis of high resolution whole-genome sequencing (WGS) data to define structural rearrangements and copy number signatures-based associated with DNA repair deficiencies in metastatic castration resistant prostate cancer (mCRPC).
The purpose of our project is to derive genomic signatures based on presence of structural rearrangements and copy number from …
Kankers zullen steeds vaker voldoen aan de definitie van ‘zeldzaam’ als het gaat om de moleculaire profielen die elke tumor uniek maakt. Hoe meer onderzoek we hiernaar doen, hoe beter we in de toekomst elke patiënt een op maat gemaakte behandeling kunnen aanbieden. Whole genome sequencing en studies als DRUP leveren hier een belangrijke bijdrage aan.